DK3601268T3 - Fremgangsmåde til fremstilling af 6-(cyclopropanamido)-4-((2-methoxy-3-(1- methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazin-3- carboxamid - Google Patents
Fremgangsmåde til fremstilling af 6-(cyclopropanamido)-4-((2-methoxy-3-(1- methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazin-3- carboxamid Download PDFInfo
- Publication number
- DK3601268T3 DK3601268T3 DK18718340.5T DK18718340T DK3601268T3 DK 3601268 T3 DK3601268 T3 DK 3601268T3 DK 18718340 T DK18718340 T DK 18718340T DK 3601268 T3 DK3601268 T3 DK 3601268T3
- Authority
- DK
- Denmark
- Prior art keywords
- methyl
- cyclopropanamido
- triazol
- pyridazine
- carboxamide
- Prior art date
Links
- -1 CYCLOPROPANAMIDO Chemical class 0.000 title 2
- DMYLUKNFEYWGCH-UHFFFAOYSA-N pyridazine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=N1 DMYLUKNFEYWGCH-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/03—Monoamines
- C07C211/04—Mono-, di- or tri-methylamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/09—Diamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/08—Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C241/02—Preparation of hydrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
- C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478789P | 2017-03-30 | 2017-03-30 | |
| PCT/US2018/025100 WO2018183649A1 (en) | 2017-03-30 | 2018-03-29 | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3601268T3 true DK3601268T3 (da) | 2021-05-03 |
Family
ID=62002470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18718340.5T DK3601268T3 (da) | 2017-03-30 | 2018-03-29 | Fremgangsmåde til fremstilling af 6-(cyclopropanamido)-4-((2-methoxy-3-(1- methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazin-3- carboxamid |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20200239449A1 (da) |
| EP (4) | EP3882237B1 (da) |
| JP (5) | JP7113023B2 (da) |
| KR (2) | KR20190133725A (da) |
| CN (4) | CN110475774B (da) |
| AU (3) | AU2018244451B2 (da) |
| BR (2) | BR112019020169A2 (da) |
| CA (2) | CA3058177A1 (da) |
| CY (1) | CY1124194T1 (da) |
| DK (1) | DK3601268T3 (da) |
| EA (2) | EA201992300A1 (da) |
| ES (1) | ES2864450T3 (da) |
| HR (1) | HRP20210764T1 (da) |
| HU (1) | HUE054886T2 (da) |
| IL (3) | IL269586B (da) |
| LT (1) | LT3601268T (da) |
| MX (4) | MX2019011231A (da) |
| PL (1) | PL3601268T3 (da) |
| PT (1) | PT3601268T (da) |
| RS (1) | RS61816B1 (da) |
| SG (2) | SG11201909018VA (da) |
| SI (1) | SI3601268T1 (da) |
| WO (2) | WO2018183656A1 (da) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2922846B1 (en) * | 2012-11-08 | 2018-10-03 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha |
| RS61816B1 (sr) * | 2017-03-30 | 2021-06-30 | Bristol Myers Squibb Co | Postupak za pripremu 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazin-3-karboksamida |
| JP2021525734A (ja) * | 2018-05-31 | 2021-09-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ６−（シクロプロパンカルボキサミド）−４−（（２−メトキシ−３−（１−メチル−１ｈ−１，２，４−トリアゾール−３−イル）フェニル）アミノ）−ｎ−（メチル−ｄ３）ピリダジン−３−カルボキサミドの結晶形態 |
| CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
| JP2022536489A (ja) * | 2019-06-12 | 2022-08-17 | ブリストル－マイヤーズ スクイブ カンパニー | ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶性塩形態 |
| AU2020348783A1 (en) | 2019-09-18 | 2022-03-31 | Bristol-Myers Squibb Company | Extended release dosage forms for Tyk2 inhibitors |
| US20230039086A1 (en) * | 2019-12-17 | 2023-02-09 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Bms-986165 crystal form, preparation method therefor and use thereof |
| WO2021143430A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型及其制备方法和用途 |
| US20230049130A1 (en) * | 2020-01-19 | 2023-02-16 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Deucravacitinib crystal form, preparation method therefor and use thereof |
| CN115003667A (zh) * | 2020-02-26 | 2022-09-02 | 百济神州有限公司 | Tyk-2抑制剂 |
| CN113735836B (zh) * | 2020-05-28 | 2023-05-30 | 江苏先声药业有限公司 | 哒嗪类化合物及其应用 |
| CN113773262A (zh) * | 2020-06-09 | 2021-12-10 | 江苏先声药业有限公司 | 哒嗪类化合物 |
| TW202214603A (zh) * | 2020-07-24 | 2022-04-16 | 大陸商上海翰森生物醫藥科技有限公司 | 一種噠嗪類衍生物游離鹼晶型及其製備方法和應用 |
| WO2022021684A1 (zh) * | 2020-07-31 | 2022-02-03 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型csv及其制备方法和用途 |
| EP4213813A1 (en) | 2020-09-18 | 2023-07-26 | Bristol-Myers Squibb Company | Dosage forms for tyk2 inhibitors comprising swellable cores |
| CN116615200A (zh) * | 2020-10-20 | 2023-08-18 | 杭州领业医药科技有限公司 | 哒嗪衍生物的晶型 |
| CA3206254A1 (en) | 2021-01-29 | 2022-08-04 | Victor W. Rosso | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| EP4313974A1 (en) | 2021-03-29 | 2024-02-07 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| BR112023023425A2 (pt) | 2021-05-14 | 2024-01-30 | Bristol Myers Squibb Co | Compostos heterocíclicos substituídos |
| KR20240050380A (ko) | 2021-08-20 | 2024-04-18 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의결정 형태 |
| WO2023049241A1 (en) * | 2021-09-23 | 2023-03-30 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
| WO2023076515A1 (en) | 2021-10-28 | 2023-05-04 | Bristol-Myers Squibb Company | Topical formulations of deucravacitinib |
| WO2023102085A1 (en) | 2021-12-01 | 2023-06-08 | Teva Czech Industries S.R.O. | Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates |
| US20230296250A1 (en) * | 2022-03-21 | 2023-09-21 | General Electric Company | Turbine engine combustor and combustor liner |
| WO2023181075A1 (en) * | 2022-03-24 | 2023-09-28 | Dr. Reddy's Laboratories Limited | Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof |
| CN114989103A (zh) * | 2022-06-09 | 2022-09-02 | 杭州科巢生物科技有限公司 | 一种2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯胺的制备方法 |
| WO2024017150A1 (zh) * | 2022-07-18 | 2024-01-25 | 苏州鹏旭医药科技有限公司 | 一种氘可来昔替尼的合成方法 |
| WO2024088282A1 (zh) * | 2022-10-28 | 2024-05-02 | 浙江华海药业股份有限公司 | 一种哒嗪酰胺类化合物、其药物组合物及其作为tyk2抑制剂的用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000075113A1 (fr) | 1999-06-09 | 2000-12-14 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveaux derives carboxamide heterocycliques |
| US7507832B2 (en) | 2003-12-22 | 2009-03-24 | Eli Lilly And Company | Triazole PPAR modulators |
| JP5114411B2 (ja) * | 2005-09-29 | 2013-01-09 | ビーエーエスエフ ソシエタス・ヨーロピア | アルミノケイ酸塩と酸化アルミニウムを含有する成形体ならびにメチルアミンの連続的製法 |
| AU2008206045A1 (en) | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of MEK |
| IN2012DN02679A (da) * | 2009-10-12 | 2015-09-04 | Bayer Cropscience Ag | |
| WO2011109799A1 (en) * | 2010-03-05 | 2011-09-09 | Karyopharm Therapeutics, Inc. | Nuclear transport modulatiors and uses thereof |
| JP5878178B2 (ja) | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | １，２，４−トリアジン−６−カルボキサミド誘導体 |
| WO2013091011A1 (en) | 2011-12-21 | 2013-06-27 | Biota Europe Ltd | Heterocyclic urea compounds |
| EP2802567B1 (en) | 2012-01-10 | 2017-03-01 | F. Hoffmann-La Roche AG | Pyridazine amide compounds and their use as syk inhibitors |
| WO2013171643A1 (en) | 2012-05-14 | 2013-11-21 | Piramal Enterprises Limited | An improved process for preparation of irbesartan |
| EP2922846B1 (en) * | 2012-11-08 | 2018-10-03 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| RS61816B1 (sr) * | 2017-03-30 | 2021-06-30 | Bristol Myers Squibb Co | Postupak za pripremu 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazin-3-karboksamida |
| JP2021525734A (ja) * | 2018-05-31 | 2021-09-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ６−（シクロプロパンカルボキサミド）−４−（（２−メトキシ−３−（１−メチル−１ｈ−１，２，４−トリアゾール−３−イル）フェニル）アミノ）−ｎ−（メチル−ｄ３）ピリダジン−３−カルボキサミドの結晶形態 |
-
2018
- 2018-03-29 RS RS20210559A patent/RS61816B1/sr unknown
- 2018-03-29 EA EA201992300A patent/EA201992300A1/ru unknown
- 2018-03-29 PT PT187183405T patent/PT3601268T/pt unknown
- 2018-03-29 ES ES18718340T patent/ES2864450T3/es active Active
- 2018-03-29 CN CN201880021649.8A patent/CN110475774B/zh active Active
- 2018-03-29 KR KR1020197031634A patent/KR20190133725A/ko not_active Application Discontinuation
- 2018-03-29 SG SG11201909018V patent/SG11201909018VA/en unknown
- 2018-03-29 CA CA3058177A patent/CA3058177A1/en active Pending
- 2018-03-29 CN CN202310263681.XA patent/CN116354939A/zh active Pending
- 2018-03-29 EP EP21155321.9A patent/EP3882237B1/en active Active
- 2018-03-29 CN CN201880022423.XA patent/CN110914260A/zh active Pending
- 2018-03-29 IL IL269586A patent/IL269586B/en unknown
- 2018-03-29 MX MX2019011231A patent/MX2019011231A/es unknown
- 2018-03-29 US US15/767,388 patent/US20200239449A1/en not_active Abandoned
- 2018-03-29 CN CN202310552731.6A patent/CN116813561A/zh active Pending
- 2018-03-29 SG SG11201908947Q patent/SG11201908947QA/en unknown
- 2018-03-29 DK DK18718340.5T patent/DK3601268T3/da active
- 2018-03-29 JP JP2019553452A patent/JP7113023B2/ja active Active
- 2018-03-29 EP EP23209227.0A patent/EP4296258A3/en active Pending
- 2018-03-29 PL PL18718340T patent/PL3601268T3/pl unknown
- 2018-03-29 HU HUE18718340A patent/HUE054886T2/hu unknown
- 2018-03-29 BR BR112019020169A patent/BR112019020169A2/pt active Search and Examination
- 2018-03-29 LT LTEP18718340.5T patent/LT3601268T/lt unknown
- 2018-03-29 WO PCT/US2018/025114 patent/WO2018183656A1/en unknown
- 2018-03-29 WO PCT/US2018/025100 patent/WO2018183649A1/en unknown
- 2018-03-29 SI SI201830252T patent/SI3601268T1/sl unknown
- 2018-03-29 AU AU2018244451A patent/AU2018244451B2/en active Active
- 2018-03-29 JP JP2019553556A patent/JP7260481B2/ja active Active
- 2018-03-29 US US16/498,442 patent/US10899745B2/en active Active
- 2018-03-29 IL IL269594A patent/IL269594B2/en unknown
- 2018-03-29 BR BR112019020163A patent/BR112019020163A2/pt unknown
- 2018-03-29 AU AU2018244916A patent/AU2018244916B2/en active Active
- 2018-03-29 CA CA3058209A patent/CA3058209A1/en active Pending
- 2018-03-29 KR KR1020197031635A patent/KR102642407B1/ko active IP Right Grant
- 2018-03-29 EA EA201992308A patent/EA201992308A1/ru unknown
- 2018-03-29 EP EP18718340.5A patent/EP3601268B1/en active Active
- 2018-03-29 MX MX2019011092A patent/MX2019011092A/es unknown
- 2018-03-29 IL IL305615A patent/IL305615A/en unknown
- 2018-03-29 EP EP18718991.5A patent/EP3601270A1/en active Pending
-
2019
- 2019-09-20 MX MX2022010496A patent/MX2022010496A/es unknown
- 2019-09-20 MX MX2022010495A patent/MX2022010495A/es unknown
-
2020
- 2020-12-22 US US17/131,718 patent/US11649226B2/en active Active
-
2021
- 2021-04-29 CY CY20211100374T patent/CY1124194T1/el unknown
- 2021-05-13 HR HRP20210764TT patent/HRP20210764T1/hr unknown
- 2021-08-11 US US17/400,100 patent/US20210371404A1/en active Pending
- 2021-11-01 AU AU2021261839A patent/AU2021261839B2/en active Active
-
2022
- 2022-07-25 JP JP2022117894A patent/JP7457758B2/ja active Active
-
2023
- 2023-01-27 JP JP2023010810A patent/JP7476370B2/ja active Active
- 2023-04-13 US US18/134,564 patent/US20230271946A1/en active Pending
- 2023-12-11 JP JP2023208420A patent/JP2024037836A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3601268T3 (da) | Fremgangsmåde til fremstilling af 6-(cyclopropanamido)-4-((2-methoxy-3-(1- methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazin-3- carboxamid | |
| DK3978580T3 (da) | Stabiliserede fluorolefinsammensætninger og fremgangsmåde til fremstilling, oplagring og anvendelse deraf | |
| CL2020002791A1 (es) | Dispositivos y métodos para engastar implantes protésicos. | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3755703T3 (da) | N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft | |
| DK3340981T3 (da) | Aryl, heteroaryl og heterocykliske forbindelser til behandling af medicinske forstyrrelser | |
| DK3402499T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes | |
| DK3385262T3 (da) | 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf | |
| DK3330258T3 (da) | 1, 3, 5-triazinderivat og fremgangsmåde til anvendelse af samme | |
| ZA202004692B (en) | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) | |
| DK3258919T4 (da) | Næsepulverformulering til behandling af hypoglykæmi | |
| HK1255438A1 (zh) | 用於治療癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯並呋喃-2-基)甲基)丙烯酰胺 | |
| DK3377109T3 (da) | Fremgangsmåde til fremstilling af en tørpulverformulering, som omfatter anticholinergikum, corticosteroid og beta-adrenergikum | |
| DK3797107T3 (da) | Heterokondenserede pyridonforbindelser og anvendelse deraf som idh- hæmmere | |
| ZA202003676B (en) | Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents | |
| SI3658547T1 (sl) | Postopek za pripravo n-(5-(4-(4-formil-3-fenil-1h-pirazol-1-1l)pirimidin-2-ilamino)-4-metoksi -2-morfolinofenil)akrilamida | |
| DK3589612T3 (da) | Fremgangsmåde til fremstilling af fluoralkylnitriler og de tilsvarende fluoralkyltetrazoler | |
| DK3456712T3 (da) | Hidtil ukendte 2,4,6-trisubstitueret S-triazinforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| DK3476838T3 (da) | Fremgangsmåde til fremstilling af azoxystrobin | |
| DK3375295T3 (da) | Fremgangsmåde til bearbejdning af grønne kaffeebønner | |
| DK3589622T3 (da) | Fremgangsmåde til fremstilling af 3,7-bis(dimethylamino)phenothiazin-5-yliumiodid | |
| DK3621941T3 (da) | Anvendelse af precursorer til fremstilling af carbon-11-mærkede aminosyrer og derivater deraf | |
| DK3612535T3 (da) | Fremgangsmåde til fremstilling af pirlindolenantiomerer og salte heraf | |
| DK3585785T3 (da) | Fremgangsmåde til fremstilling af methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1h | |
| ZA201802523B (en) | Thermodynamically stable crystal modification of 2¿methyl¿n¿(5¿methyl¿1,3,4¿oxadiazole¿2¿yl)¿3¿(methylsulfonyl)¿4¿(trifluoromethyl)benzamide |